Sage Group is attending BioEurope Spring 2023 from 20-23 March 2023! Please click here to setup a call with us in advance or book on the partnering sessions!

The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial development partners for its later stage, highly novel asset for treatment of serious cardiopulmonary disease. Respira’s initial pipeline is targeting two indications with large unmet medical needs, with market potentials likely in excess of $1Bn each. Respira is a privately funded US-based company focused on treatment of cardiopulmonary disease

The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; https://discoverybiomed.com/). DBM is a revenue-generating pre-clinical CRO based in Birmingham, Alabama focused on integrating biologically- and disease-relevant human cell cultures and lines into all relevant steps of Drug Discovery. Please request from Sage a non-confidential Information Memorandum on DBM. DBM is the one of the first companies to enable extension of preclinical testing to hum